Last reviewed · How we verify

KN060 Low — Competitive Intelligence Brief

KN060 Low (KN060 Low) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PD-1/PD-L1 inhibitor. Area: Oncology.

phase 2 PD-1/PD-L1 inhibitor PD-L1 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

KN060 Low (KN060 Low) — Suzhou Alphamab Co., Ltd.. KN060 Low is a monoclonal antibody targeting PD-L1.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
KN060 Low TARGET KN060 Low Suzhou Alphamab Co., Ltd. phase 2 PD-1/PD-L1 inhibitor PD-L1
DURVALUMAB DURVALUMAB marketed Programmed Death Ligand-1 Blocker [EPC] PD-L1 2017-01-01
AVELUMAB AVELUMAB marketed Programmed Death Ligand-1 Blocker [EPC] PD-L1 2017-01-01
Adebrelimab combined with SOX regimen Adebrelimab combined with SOX regimen Yang Jianjun, PhD marketed PD-L1 inhibitor PD-L1
Pf-06865571 pf-06865571 Pfizer marketed Monoclonal antibody PD-1/PD-L1 pathway
Cisplatin / Carboplatin，Gemcitabine，Cindilimab Cisplatin / Carboplatin，Gemcitabine，Cindilimab People's Hospital of Quzhou marketed Combination chemotherapy with immune checkpoint inhibitor DNA (platinum agents, gemcitabine); PD-L1 (cindilimab)
Pf-06835375 pf-06835375 Pfizer marketed Immunotherapy PD-L1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PD-1/PD-L1 inhibitor class)

  1. Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 3 drugs in this class
  2. AstraZeneca · 2 drugs in this class
  3. Cancer Institute and Hospital, Chinese Academy of Medical Sciences · 1 drug in this class
  4. Hanlim Pharm. Co., Ltd. · 1 drug in this class
  5. EMD Serono · 1 drug in this class
  6. EMS · 1 drug in this class
  7. Fujian Cancer Hospital · 1 drug in this class
  8. Elixiron Immunotherapeutics (Hong Kong) Ltd. · 1 drug in this class
  9. Cellvax Therapeutics Inc · 1 drug in this class
  10. Anhui Shi, MD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). KN060 Low — Competitive Intelligence Brief. https://druglandscape.com/ci/kn060-low. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: